Влияние терапии аторвастатином на секректорную фосфолизу А2 группы ПА, липидный состав и модификацию липопротеидов низкой плотности у больных ишемической болезнью сердца с дислипидемией
Диссертация
В этой работе, впервые в нашей стране, продемонстрировано влияние терапии аторвастатином на концентрацию и каталитическую активность секФЛА2(ПА), оценено влияние гиполипидемической терапии на липидный состав и модификацию ЛНП под действием секФЛА2(ПА) у больных ИБС с дислипидемией. Показано, снижение концентрации и каталитической активности секФЛА2(ПА) на фоне гиполипидемической терапии… Читать ещё >
Содержание
- страницы
- Список сокращений
- Введение
- Глава I. Обзор литературы
- 1. 1. Роль хронического воспаления в процессах атерогенеза
- 1. 2. Биологические эффекты секФЛА2(11А), ее роль в атерогенезе 8−20 1.2.1 Семейство фосфолипаз, механизм действия й способы регуляции секреции фермента
- 1. 2. 2. Биологические эффекты секФЛА2(ПА) и ее метаболитов
- 1. 2. 3. Взаимодействие секФЛА2(ПА) с липопротеидами
- 1. 2. 4. Роль секФЛА2(ПА) в развитии и прогрессировании атеросклероза
- 1. 2. 5. Липид — ассоциированная ФЛА
- 1. 3. Роль статинов в лечение дислипопротеинемий у больных ИБС
- 1. 3. 1. Общие сведения о механизме действия статинов, их влиянии на процессы атерогенеза
- 1. 3. 2. Место аторвастатина среди других ингибиторов ГМГ-КоА-редуктазы
- 1. 3. 3. Статины как противовоспалительные средства 34−39 1 А
- 2. 1. Клиническая характеристика больных
- 2. 2. Клинико-инструментальные методы исследования 46−47 2.3 Биохимические методы исследования 47−50 2.4. Методы статистического анализа
- 3. 2. Влияние терапии аторвастатином на липидный спектр у больных ИБС с дислипидемией
- 3. 2. 1. Влияние терапии аторвастатином на показатели липидного спектра плазмы крови у больных ИБС с изолированной гиперхолестеринемией
- 3. 2. 2. Влияние терапии аторвастатином на показатели липидного спектра в плазме крови у больных ИБС со смешанной гиперлипидемией
- 3. 3. Влияние терапии аторвастатином на концентрацию СРБ у больных ИБС с дислипидемией
- 3. 4. Влияние терапии аторвастатином на концентрацию и каталитическую активность секФЛА2(ПА) у больных ИБС с дислипидемией
- 3. 5. Влияние терапии аторвастатином на липидный состав частицы ЛНП у больных ИБ С с дислипидемией
- 3. 6. Влияние терапии аторвастатином на процесс модификации ЛНП под действием секФЛА2(ПА) у больных ИБС с дислипидемией
- 3. 7. Влияние терапии аторвастатином на клинико-биохимические показатели у больных ИБС с дислипидемией
Список литературы
- Белова, А А., Оглобина О. Г., Белов A.A., Кухарчук В. В. Процессы модификации липопротеинов, физиологическая и патогенетическая роль модифицированных липопротеинов. Вопросы медицинской химии 2000−1:42−47.
- Ваулин H.A., Грацианский H.A. Нестабильная стенокардия. Маркеры воспаления при краткосрочном применении правастатина. Кардиология 2001−11:4−10.
- Всероссийское научное общество кардиологов. Российские рекомендации. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Москва 2005.
- Доборджгинидзе Л.М., Грацианский H.A. Дислипидемия: липиды и липопротеиды, метаболизм и участие в атерогенезе. РМЖ 2000−8-7.
- Климов А.Н., Никульчева Н. Г. Обмен липидов и липопротеидов и его нарушения. Санкт-Петербург «Питер» 1999.
- Коротаева A.A., Чеглаков И. Б., Морозкин А. Д., Суслова И. В., Проказова Н. В. Влияние лизофосфатидилхолина на структуру и функцию липоротеидов низкой плотности. Биологич. мембраны 1996−5:484−496.
- Ларский Э.Г., Комелькова Л. В. Белки острой фазы: современное состояние вопроса. М.Р.Ж. раздел XXII 1988−12:33−37.
- Лупанов В.П. Пробы с физическими нагрузками при ишемической болезни сердца: критерии, достижения, перспективы. Кардиология 1984- 4: 119−124.
- Лякишев A.A. Применение статинов для лечения больных атеросклерозом. РМЖ. Кардиология. 2000−1:28−32.
- Нагорнев В.А. Атеросклероз и иммунное воспаление. БЭБМ 1996−122:4−8.
- Нагорнев В.А., Назаров П. Г., Полевщиков A.B. Атерогенез и реакция «острой фазы» печени. АРХПат. 1998−6:67−74.
- Нагорнев В.А., Яковлева O.A., Мальцева C.B. Атерогенез как отражение развития иммунного воспаления в сосудистой стенке. ВестРАМН 2000−10−45−50.
- Насонов У. Л. Маркеры воспаления и атеросклероз: значение С-реактивного белка. Кардиология 1999−2:81−86.
- Проказова Н. В., Звездина Н. Д., Коротаева A.A. Влияние лизофосфатидилхолина на передачу трансмембранного сигнала внутрь клетки. Биохимия 1998−63:38−46.
- Репин B.C., Смирнов В. Н. Фундаментальные науки против атеросклероза. М."Союзмединформ" 1989: 71.
- Самойленко Е.Ю., Наумов В. Г., Творогова М.Г, Ежов М. В., Сергиенко И. В., Кухарчук В. В. Влияние терапии аторвастатином на показатели постпрандиальной липемии и факторы воспаления у больных ишемической болезнью сердца. Кардиология 2007:42(2)-4−8.
- Стрекаловский Д.В., Никифоров С. Б., Гольдберг O.A. Влияние трансплантации фетальной ткани печени на морфологические изменения при экспериментальном атеросклерозе. БЭБМ 1998- 1:134 137.
- Сумароков А.Б., Наумов В. Г., Масенко В. П. С-реактивный белок и сердечно-сосудистая патология. Тверь «ООО» Издательство" Триада". 2006, С-176.
- Творогова М.Г., Рожкова Т. А., Кухарчук В. В., Титов В. Н. Сопоставление показателей обмена липопротеинов у лиц с низкой и высокой активностью переноса эфиров холестерина. Вопросы медицинской химии 1999−4:23−28.
- Тертов В.В. Множественно-модифицированные липопротеиды низкой плотности циркулирующие в крови человека. Ангиол и Сосуд Хирург. 1999−5прил.:218−239.
- Титов В.Н. Общность атеросклероза и воспаления: специфичность атеросклероза как воспалительного процесса. Кардиология 1999−5:48−56.
- Харченко В.И., Кокорина Е. П., Корякин М. В., Вирин М. М. Смертность от основных болезней системы кровообращения в России. Российский кардиологический журнал. 2005−1(51):5−15.
- Шальнова С.А., Деев А. Д., Оганов Р. Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в российской популяции. Кардиоваскулярная терапия и профилактика 2005−4(1):4−8.
- Alfon J., Palazon P.C., Royo T., Badimon L. Effects of statins in thrombosis and aortic lesion development in adyslipidemic rabbit model. Thromb Haemost 1999−81:822−827.
- American Heart Association (AHA)/ 2001 heart and stroke statistical update. Dallas: American Heart Association 2000.
- Anthonsen M.W., Sohlhaug A., Johansen B. Functional coupling between secretory and cytosolic phospholipase A2 modulates tumor necrosis factor-alpha- and interleukin-1 beta-induced NF-kappa B activation. J Biol Chem 2001- 276:30 527−30 536.
- Ascer E., Bertolami M.C., Venturinelli M.L., Bucceheri V., Souza J., Nicolau J.C., Ramires J.A., Serrano C.V. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004- 177(1):161−166.
- Barnes P.J., Karin M. Nuclear factor-k B-a pivotal transcription factor in chronic inflammatory disease. N Engl Med J 1997- 336:1066−1071.
- Berk BC., Wentraub W.S., Alexander R.W. Elevation of C-reactive protein in acute coronary artery disease. A J Cardiol 1990- 65:168−172.
- Biascucci L.M., Vitelli A., Liuzzo G. Elevated levels of interleukin-6 in unstable angina. Circulation 1997- 96:2099.
- Blake G.L., Ridker P.M. Are statins anti-inflammatory? Curr Control Trials Cardiovasc Med 2000- 1:161−165.
- Callahan A. Cerebrovascular disease and statins: a potential addition to the therapeutic armamentarium for stroke prevention. Am J Cardiol 2001- 88: Suppl:33J-37J.
- Capewell S. et al. Trends in case-fatality in 117,718 patients admitted with acute myocardial infarction in Scotland. European Society of Cardiology. 2000−21:1833−1840
- Chen L., Liang B., Froese D.E. Oxidative modification of low density lipoprotein in normal and hyperlipidemic patients: effect of Iysophosphadylcholine composition on vascular relaxation. J Lipid Res 1997- 38:546−553.
- Chesquiere S.A., Hofker M.H., Winther M. The role phospholipase in lipid modification and atherosclerosis. Cardiovasc Toxicol 2005−5:161−82
- Cummings B.S., McHowat J., Schnellmann R.G. Phospholipase A (2)s in cell injury and death. J Pharmacol Exp Ther 2000- 294:793−799.
- DALI-Study Group. Van de Ree, Huisman M.V., Princen H.M.G., Meinders A.E., Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003−166:129−135.
- Dallinga-Thie G. M, van Tol A., Hattori H., Rensen P.C., Sijbrands E.J. Plasma phospholipids transfer protein activity is decreased in type 2 diabetes during treatment with atorvastatin: a role for apolipoprotein E. Diabetes 2006−55(5):1491−6.
- Davignon J. Advances in drags treatment of dyslipidemia: focus on atorvastatin. Can J.Cardiol. 1998- 14:28B-38B.
- Doggrell S.A. Relating statin therapy to C-reactive protein level. Expert Opin Pharmacother 2005−6(9): 1597−600.
- Downs J.R., Clearfield M., Weis S. For the AFCAPS/ TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in menand women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998−279:1615−1622.
- Elinder L.S., Dumitrescu A., Larsson P., Hedin U., Frostegard J., Claesson
- H.E: Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall. Arterioscler Thromb Vase Biol 1997- 17: 22 572 263.
- European Guidelines on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003−24:17:1601 -1610.
- Feron O., Dessy C., Desager J.P. et al. Hydroxy-methylglutaril coenzyme A reductase inhibition promotes endothelial nitric oxide synthase action through a decreases in carveolin abundance. Circulation 2001- 103:113−118.
- Field K.M. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein level. Pharmacotherapy 2005−25:1367−77.
- Frostegard J., Ulfgren AK., Nyberg P., Hedin., Swedenborg J., Andersson U., Hansson G.K. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory and macrophage-stimulating cytokines. Atherosclerosis 1999−145:33−4.
- Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 1994−90:2126−2114.
- Hajjar D.P., Pomerantz K.B. Signal transduction in atherosclerosis: integration of cytokines and the eicosanoid network. Faseb J 1992−6:2933−2941.
- Hansson G.K. Cell-mediated immunity in atherosclerosis. Curr Opin Lipidol 1997−8:301−311.
- Hansson G.K. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vase Biol. 2001−21:1876−90.
- Hart-Camejo E., Camejo G. Potential involvement of type II phospholipase A2 in atherosclerosis. Aterosclerosis 1997−132:1−8.
- Hart-Camejo E., Camejo G., Peilot H., Oorni K., Kovanen P. Phosphlipase A2 in Vascular Disease. Circulation Research 2001−89:298−304.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individual a randomized placebo-controlled trial. Lancet 2002−360:9326:7−22.
- Hurt-Camejo E., Camejo G., and Sartipy P. Phospholipase A2 and small, dense low-density lipoprotein. Curr Opin Lipidol 2000- 11:465−471.
- Innis-Whitehouse W., Li X., Bakker-Arkema R., Black D. and Brown W.V. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin. Metabolism 2000−49:167−177.
- Insull W., Kafonek S., Goldner D. Comparison of efficacy and safety of atorvastatin with simvastatin, at six weeks. ASSET Investigators. Am.J.Card- 2002:89(6):667−71.
- Jeffrey S.C., Tremblay M., Batal R., Jacques H., Veilleux L. et.al. Effect of atorvastatin on plasma apoE metabolism in patients with combined hyperlipidemia. J. of Lipid Research 2002−43:1464−1471.
- Jialal I., Stein D., Grandy S.M., Adams-Huet B., Deveraj S. Effect of hydroxy-methyl-glutaryl coenzyme A reductase inhibitor therapy on high sensitive C-reactive protein level. Circulation 2001−103:1933−5.
- Jones P.H., Kafonek S., Laurora I. et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (The Curves study). Am J Cardiol 1998−81:582−587.
- Jones P.H., McKenney J.M., Karalis D.G. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia. Evide. Based Cardiocasc Med. 2005- 9(2):98−101.
- Kalayoglu M.V. Chlamydia heart shock protein 60 and lip polysaccharide: potential virulence determinants in atherogenesis. Curr Drug Targets Inflamm Allergy. 2002−3:249−255.
- Karalis D.G., Ross A.M., Vacari R.M. Comparison of efficacy and safety of atorvastatin and simvastatin in patients with Dyslipidemia with and without coronary heart disease. Am J Cardiol 2002−89(6):667−671.
- Karalis D.S., Ishisaka D.Y., Luo D., Ntanios F., Wun C. C, Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia. A J Cardiol 2007−100(3):445−9.
- Kleinman Y., Krul E.S., Burnes M., Aronson W., Pfleger B., Schonfeld G. Lipolysis of LDL with phospholipase A2 alters the expression of selectedapoB-100 epitopes and the interaction of LDL with cells. J Lipid Res 1988−29:729−43.
- Kluft C., Maat D., Leuven JA., Mohrschladt B.J. Statins and C-reactive protein. Lancet 1999−353:1274−1275.
- Kohji Hanasnki. Mammalian Phospholipase A2: Phospholipase A2 Receptor. Biol Pharm Bui 2004−27(8):1165−1167.
- Kougias P., Chai H., Lin P.H., Lumsden A.B., Yao Q., Chen C. Lysophosphatidylcholine and secretory phospholipase A2 in vasculardisease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 2006−12:RA5−16.
- Kovanen P., Pentikainen M.O. Secretory Group II Phospholipase A2. A Newly Recognized Acute-Phase Reactant with a Role in Aterogenesis. Circ Res. 2000−86(6):610−612.
- Kovanen T., Pentikainen M.O. Circulating lipoproteins as proinflammatory and anti-inflammatory particles in atherogenesis. Curr. Opin Lipid. 2003−14:411−419.
- Krijnen P.A., Meischi C., Nijmeijer R., Visser C.A., Hack C.E., Niessen H.W. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction? Cardiovasc Hematol Disord Drug Targets 2006−6:113−123.
- Kugiyama K., Kerns S.A., Morrisett J.D., Roberts R. and Henry P.D. Impairment of endothelium-depended arterial relaxation by lysolecithin in low-density lipoproteins. Nature 1990−344:160−162.
- Kume N., Gimbrone M.A. Lysophosphatidylcholine transcriptionally induces growth factor gene expression in cultured human endothelial cells. J Clin Invest 1994−93:907−911.
- Laufs U., Gertz K., Huang P. et al. Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protect from cerebral ischemia in normocholesterolemic mice. Stroke 2000−31:2442−2449.
- Laufs U., Wassmann S., Hilgers S. et al. Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. Circulation 2001−104:376−379.
- Lekakis J.P., Papamichael C.M., Ciproneriu A.T. et al. Atherosclerotic changes of extracoronary arteries are associated with the extent of coronary atherosclerosis. Am J Cardiol 2000−85:949−952.
- Liao J.K. Effects of Statins on 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibition Beyond low-Density Lipoprotein Cholesterol. Am J Cardiol 2005−96:24F-33 °F.
- Libbi J. Molecular bases of the acute coronary syndromes. Circulation 1995−91:2844−2850.
- Maron D.J., Fazio S., Linton Mac R. F. Current perspectives on statins. Circulation 2000- 101:207−213.
- Martin G., Duez H., Blanquart C. Statin-induced inhibition the Rho-signaling pathway activates PPARa and induces HDL apoA-I. J Clin Invest 2001−107:1423−1432.
- Marz W., Wollseklager H., Kilins G. et al. Safety of low-density lipoprotein cholesterol reduction with atorvastatin versus simvastatin incoronary heart disease population (the Target Tangible Trial). Am J Cardiol 1999−84:7−13
- Mason R.P., Walter M.F., Charles A. D. and Robert F. J. Intermolecular Differences of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Contribute to Distinct Pharmacologic and Pleiotropic Actions. Am J Cardiol. Supplem 2005−96:11F-23 °F.
- Mc Farlant S.I., Banerji M., Sowers J.R. Insulin resistant and cardiovascular diseases. J Clin Endocrinol Metab 2001−86:713−718.
- Menschikowski M., Hagelgans A., Siegert G. Secretory phospholipase A2 of IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins Other Lipid Mediat 2006−79(l-2)-l-33.
- Menshikowski M., Muller E. Secretory nonpancreatic (group II) phospholipase A2 releases precursor of important mediators of inflammation from phospholipids. Atherosclersis 1999−144:73−78.
- Milionis H.J., Rizos E., Kostapanos M., Filippatos T.D., Gazi I.F., Ganotakis E.S., Goudevenos J., Mikhailidis D.P., Elisaf M.S. Treating to target patients with primary hyperlipidaemia- comparison of the effects of
- ATOrvastatin and ROSuvastatin (the ATOROS study). Curr Med Res Opin 2006−22(6): 1123−31.
- Mitsutake R., Miura S., Okamura K., Niimura H., Kawamura A., Saku K. Successful intensive lipid-lowering therapy using atorvastatin stabilizes coronary artery plaque as assessed by multi-detector row computed tomography. Intern Med 2007−46(12):859−63.
- Morrow D.A., Ridker P.M. High sensivity C-reactive protein: A novel risk marker in cardiovascular disease. Prev Cardiol 1999- 1:13−16,41.
- Murakami M., Kudo I. New phospholipase A2 isozymes with a potential role in atherosclerosis. Curr. Opin Lipid 2003−14:431−436.
- Nawrocki J.W., Wtiss S.R., Davidson M.H. et al. Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin a new HMS-CoA reductase inhibitor. Arterioscler Thromb Vase Biol 1995−15:678−682.
- Nevalainen T. J, Haapamaki M.M. Gronroo J. M: Roles of secretory phospholipase A2 in inflammatory diseases and trauma. Biochim Biophys Acta2000−1488: 83−90.
- Nevalainen T.J., Gronroos J. Serum Phospholipase A2 in Inflammatory Diseases. Prog. Surg. Basel. 1997−24:104−109.
- Newman B.C., Palmary G., Sielbershats H., Szarek M. Safety of atorvastatin derived from analysis of 44 completed trails in 9,416 patients. Am J Cardiol 2003−92:670−676.
- Newman C., Tsai J., Szarek M., Luo D., Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14 236 patients. AmJ. Cardiol 2006−97(l):61−67.
- Niessen H.W., Krijnen A J., Visser C.A., Meijer L.M., Hack C.E. Type II secretory phospholipase A2 cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes. Cardiovascular Research 2003−60:68−77.
- Nissen S.E., for the ACTIVATE Investigators. Effect of AC AT Ingibition on the Progression of Coronary Athrrosclerosis. Circulation 2005−112:3363
- Nissen S.E., Tuzcu E.M., Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. A randomized controlled trial. JAMA 2004−291:1071−1080.
- Nissen S.E., Tuzcu E.M., Schoenhagen P. Statin Therapy, LDL Cholesterol, C-Reactive Protein, and Coronary Artery Disease. New Engl J Med. 2005−352:29−38.
- Nyman K.M., Uhl W., Forsstrom J., Buchler M., Beger H.G., Nevalainen T.J. Serum phospholipase A2 in patients with multiple organ failure. J Surg Res 1996−60: 7−14.
- Ortego M., Bustos C., Hermandez- Presa M.A., Tunon J., Diaz C. Atorvastatin reduces NF-kB activation chemokine expression in vascular smooth muscul cells and mononuclear cell. Atherosclerosis 1999- 147:253 261.
- Packard C.J. A triumvirate of targets in the prevention and treatment paradigm for cardiovascular disease. Atheroscler. Suppl. 2006−7(1):21−29.
- Packard C.J. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol 2006−17(4):412−417.
- Parthasarathy S., Steinbrecher U.P., Barnett J. Essential role of phospholipase A2 activity in endothelial cell-induced modification of low density lipoprotein. Proc Natl Acad Sci USA 1985−82:3000−4.
- Pehlivanidis A., Athyros V., Demitriadis D. et al. Heart rate variability after long-term treatment with atorvastatin in hypercholesterolemic patients with or without coronary artery disease. Atherosclerosis. 2001−152:463−469.
- Piek J., Winter R. Type II secretory phospholipase A2: The emerging role of biochemical markers of plaque inflammation. Eur Heart J 2002−24:1804−1806.
- Pirillo A., Zhu W., Norata GD., Zanelli T., Barberi L., Roma P., Catapano A.L. Oxidized lipoproteins and endothelium. Clin Chem Lab Med 2000−38:155−160.
- Pitt B., Waters D., Brown W.V. et al. For Atorvastatin versus Revascularization Treatment Investigators. Aggressive lipid-lowing therapy compared with angioplasty in stable coronary artery diseases. N Engl J Med 1999−341:70−76.
- Poole A.R., Howell J.I., Lucy J.A. Lysolecithin and cell fusion. Nature 1970−227:810−814.
- Pruzanski W., Lambeau G., Lazdunski M., Cho W., Kopilov J., Kuksis A. Hydrolysis of minor glycerophospholipids of plasma lipoproteins by human group IIA, V and X secretory phospholipases A2. biochim Biophys Acta 2007−1771(1):5−19.
- Rader D.J. Inflammatory markers of coronary risk. N Engl J Med, 2000−343:1179−1182.
- Ridker P.M., Cannon C.P., Morrow D. C-Reactive Protein Level and Outcome after Statin Therapy. New Engl. J Med. 2005−352:20−28.
- Ridker P.M., Cushman M., Stampfer M.J. Plasma concentration of C-reactive protein and risk of developing peripheral vascular diseases. Circulation 1998−97:425−428.
- Ridker P.M., Hennekens C.H., Buring J.B., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl J Med. 2000−342:836−843.
- Ridker P.M., Rifai N., Pfeffer M.A. For the Cholesterol and Recurrent Events (CARE) Investigator. Long-term effects of pravastatin on plasma concentration C-reactive protein. Circulation 1999−100:230−235.
- Ridker P.M., Rifai N., Pfeffer M.A. Long-term effect of pravastatin on plasma concentration of C-reactive protein. Circulation 1999−100:230−235.
- Ridker P.M., Rifai N., Rosel L. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in prediction of first cardiovascular events. N Engl J Med 2002−347:1557−1565.
- Riesen W.F., Engler H., Risch M. et al. Short effect atorvastatin on C-reactive protein. Eur Heart j 2002−23:794−799.
- Ros E., Comez-Ceriqe J.A., Olivan J., Mostaza J.M. et al. ATOrvastatin versus bezafibrate MIXed hyperlipidemia. ATOMIX Investigators. Clin Drug Invest 2003- 23:153−65.
- Rosensen R. S. Non-lipid-lowering effects of statins on atherosclerosis. Curr Cardiol Rep 1999−1:225−32.
- Rosenson R.S. Statins in atherosclerosis- lipid-lowering agents with antioxidant capabilities. Atheroscler 2004- 173: 1−12.
- Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999−340:115−126.
- Rudel L.L., Lee R.G., Parini P. ACAT2 Is a target for treatment of coronary heart disease associated with hypercholesterolemia. Atherioscler Thromb Vase Biol 2005−25:1112−1118.
- Salbach P., Lang S., Kuchler D. et al. Short term treatment with atorvastatin: decrease of inflammatory markers and binding activity ofNF-kappa B in patient with hypercholesterolemia. Eur Heart J 2001−22:644.
- Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease- the Scandinavian Simvastatin Survival Study (SSSS). Lancet 1994−344:1383−1389.
- Schrott H, Fereshetian A.G., Knopp R.H. et al. A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin. J Cardiovasc Pharmacol Ther 1998−3(20):119−124.
- Schwemmer M., Aho H., Michel J.B. Interleukin-1 beta-induced type IIA secreted phospholipase A2 gene expression and extracellular activity in rat vascular endothelial cells. Tissue Cell 2001−33:233−240.
- Shepherd J., Blauw G.J., Murphy M.B., Bollen E.L. et al. PROSPER study group. Pravastatin in elderly individuals at risk of vascular disease
- PROSPER): a randomized controlled trial. PROspective of Study Pravastatin in the Elderly at Risk. Lancet 2002−360:1623−1630.
- Shepherd J., Codde S.M., Ford I. For the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl Med J 1995−333:1301−1307.
- Six D. A, Dennis E. A: The expanding superfamily of phospholipase A (2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1−19,2000.
- Smith D.G., Leslae S J., Szucs T.D. et al. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin (Treato-Target Study). Clin Drug Invest 1999−17:185−193.
- Standberg T.E., Vanhanen H., Tikkanen MJ. Effect of Statins on C~ reactive protein in patients with coronary artery disease. Lancet 1999−353:1274−1275.
- Stein E.A. Lane M., Laskarzewski P. Effect statins on triglyceride level. Am J Cardiol. 1998−81:27B-31B.
- Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arteriose Throm Vase Biol 2001−21:1712−9
- Tannous M., Cheung R., Vignini A. et al. Atorvastatin increase eNOS levels in human platelets of hyperlipidemic subjects. Thromb Haemost 1999−82:1390−1394.
- Thompson G.R. Plasma lipids and lipoproteins, and the hyperlipoproteindaemia. Biochem Aspects of Human Disease Blackwell, 1983:85−123.
- Triggiani M., Granata F., Oriente A., Gentile M., Petraroli A., Balestrieri B., Marone G. Secretory phospholipase A2 induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol 2002−32:67−76.
- Tselepis A.D., Chapman MJ. Inflammation, bioactive lipid and atherosclerosis: potential role of a lipoprotein-associated phospholipase A2, platetlet activating factor-acetylhydrolase. Aterosclerosis Supplements 2002−3:57−68.
- Tsimikas S., Willerson J.T., Ridker P.M. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Coll Cardiol 2006−47(8 Suppl):C 19−31.
- Vadas P., Browning J., Edelson J., Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat 1993−8:1−30.
- Valentin E., Lambeau G. Increasing molecular diversity of secreted phospholipase A2 and their receptors and binding proteins. Biochim Biophys Acta 2000−1488:59−70.
- Vasa M., Fichtlsherer S., Adler K. et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation 2001−103:2885−2890.
- Webb N. Secretory phospholipase A2 enzymes in atherogenesis. Curr. Opin Lipidol 2005- 16: 341−344.
- Weidtmann A., Scheithe R., Hrboticky N., Pietsch A., Lorenz R. and Siess W. Mildly oxidized LDL induces platelet aggregation through activation of phospholipase A2. Arterioscler Thromb Vase Biol 1995−15:1131−1138.
- Weltzien H.U. Cytolytic and membrane-perturbing properties ofphosphatidylcholine. Biochim Biophys Acta 1979−559:259−287.
- Wiklund O., Mattsson-Hulten L., Hurt-Camejo E., Oscarsson. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J. Inter. Medicin 2002- 251:338−347
- Wissen S., Smide T.J., Groot E. et al. Significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on atherosclerosis progression study. Eur J Cardiovasc Prevention Rehab 2003−10:451−455.
- Xu Q. Infections, heart shock proteins, and atherosclerosis. Curr Opin Cardiol. 2003−18:245−52.
- Zhu Q., McMaster J., Mumin D. et al. Effects of atorvastatin treatment on the oxidative modified low density lipoprotein in hyperlipidemic patients. Mol Cell Biochem 2000−207:9−17.
- Zhu Y., Lin J.H., Liao H.L., Verna L., Stemerman M.B. Activation of ICAM-1 promoter by lysophosphatidylcholine: possible involvement of protein tyrosine kinases. Biochim Biophys Acta 1997−1345:93−98.